This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?
by Zacks Equity Research
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.
Chemed (CHE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 5.71% and 2.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid
by Zacks Equity Research
The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.
Moving Average Crossover Alert: Chemed Corp (CHE)
by Zacks Equity Research
Chemed Corporation (CHE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Why Is Chemed (CHE) Down 2.6% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
CVS Health's (CVS) Front Store Sales Robust, LTC Suffers
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
Encompass Health (EHC) to Spin Off Unit to Streamline Business
by Zacks Equity Research
Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Looking for a Growth Stock? 3 Reasons Why Chemed (CHE) is a Solid Choice
by Zacks Equity Research
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Encompass Health (EHC) to Build Rehabilitation Hub in Illinois
by Zacks Equity Research
Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?